Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-01
2006-08-01
Nickol, Gary (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388200, C530S866000, C536S023100
Reexamination Certificate
active
07084256
ABSTRACT:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.
REFERENCES:
patent: 4191668 (1980-03-01), Katz
patent: 4222907 (1980-09-01), Katz
patent: 4388441 (1983-06-01), Katz
patent: 4760025 (1988-07-01), Estell et al.
patent: 4782137 (1988-11-01), Hopp et al.
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5229272 (1993-07-01), Paul et al.
patent: 5236836 (1993-08-01), Paul
patent: 5240845 (1993-08-01), Fujii, deceased et al.
patent: 5538854 (1996-07-01), Faustman
patent: 5541309 (1996-07-01), Prasher
patent: 5595887 (1997-01-01), Coolidge et al.
patent: 5599538 (1997-02-01), Paul et al.
patent: 5602015 (1997-02-01), Sudhir
patent: 5608039 (1997-03-01), Pastan
patent: 5637454 (1997-06-01), Harley
patent: 5648219 (1997-07-01), MacKay et al.
patent: 5656456 (1997-08-01), Stout et al.
patent: 5658753 (1997-08-01), Paul et al.
patent: 5690933 (1997-11-01), Cobbold et al.
patent: 5792604 (1998-08-01), Jefferies et al.
patent: 5869287 (1999-02-01), Price et al.
patent: 5885793 (1999-03-01), Griffiths et al.
patent: 5906936 (1999-05-01), Eshhar et al.
patent: 5912172 (1999-06-01), Eshhar et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 6403371 (2002-06-01), Conrad et al.
patent: WO 94/08008 (1994-04-01), None
Hakim et al. Journal of Immunology, 157(12): 5503-5511, 1996.
Fielder et al. Immunotechnology, 3(3): 205-216, 1997.
Gura et al. (Science 278:1041-1042, 1997).
Burgess et al. (Journal of Cell Biology, 111:2129-2138, 1990).
Lazar et al. (Molecular and Cellular Biology 8:1247-1252, 1988).
Bowie et al. (Science 247:1306-1310, 1990).
Bodey et al. (Anticancer Research 20:2665-2676, 2000).
Shu, et al., “Secretion of a single-gene-encoded immunoglobulin from myeloma cells”,Proc. Natl. Acad. Sci. USA(1993) 90:7995-7999.
Benvenuti and Burrone, “Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined VL/VHdeterminants”,Gene Therapy(2001) 8:1555-1561.
Caspar, et al., “Idiotype vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations”,Blood(1997) 90(9):3699-3706.
De Gruijl and Curiel, “Cancer vaccine stategies get bigger and better”,Nature Medicine(1999) 5(10):1124-1125.
Donnelly, “Cancer vaccine targets leukemia”,Nature Medicine(2003) 9(11):1354-1356.
Evans and Kaye, “Vaccine therapy for cancer—fact or fiction?”Q J Med.(1999) 92:299-307.
Fitchen, et al., “Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response”,Vaccine(1995) 13:1051-1057.
Girard, et al., “Methodes d'etudes des virus”,Virologie Moleculaire(1989), Chapter 2, pp. 61-65.
Hakim, et al., “A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines”,J. Immun.(1996) 157(12):5503-5511.
Hennecke, et al., “Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology”,Protein Engineering(1998) 11(5):405-410.
Hsu, et al., “Tumor-Specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial”,Blood(1997) 89(9):3129-3135.
Jerala, et al., “Improved expression and evaluation of polyethyleneimine precipitation in isolation of recombinant cysteine proteinase inhibitor Stefin B”,Protein Expression and Purification(1994) 5:65-69.
King, et al., “DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma”,Nature Medicine(1998) 4(11):1281-1286.
Langeveld, et al., “Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide”,Vaccine(1994) 12:1473-1480.
Stemmer, et al., “Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR”,Biotech.(1993) 14(2):256-265.
Tang, et al., “Selection of linkers for a catalytic single-chain antibody using phage display technology” (1996) 271(26):15682-15686.
Tavladoraki, et al., “A single-chain antibody fragment is functionally expressed in the cytoplasm of bothEscherichia coliand transgenic plants”,European J. Biochem.(1999) 262(2):617-624.
Turner, et al., “Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology”,J. Immun. Methods(1997) 205(1):43-54.
Fiedler, et al., “Optimization of scFv antibody production in transgenic plants”,Immunotechnology(1997), 3:205-216.
Vaquero, et al., “Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves”,Proc. Natl. Acad. Sci.(1999), 96:11128-11133.
Pharmaceutical Biotechnology, “Vaccine Design: The Subunit and Adjuvant Approach.” Powell & Newman, Eds. vol. 6 pp. 389-412, (1995).
Proc. Natl. Acad. Sci. USA, McCormick et al., “Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.” vol. 96, pp. 703-708, (1999).
Lindbo John A.
McCormick Alison A.
Reinl Stephen J.
Turpen Thomas H.
Tuse Daniel
Aeder Sean E
Gallegos Thomas
Large Scale Biology Corporation
Nickol Gary
Tarcza John E.
LandOfFree
Self antigen vaccines for treating B cell lymphomas and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Self antigen vaccines for treating B cell lymphomas and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Self antigen vaccines for treating B cell lymphomas and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677021